The Role Of Fibroscan In Detecting Hepatic Fibrosis Induced By Methotrexate

Open access

Abstract

Introduction: Liver represents the main place of drug metabolisation. Drugs and toxic substances reach the level of liver after absorption at gastro-intestinal level. Drug hepatotoxicity represents an important chapter of iatrogenic pathology, because the hepatic lesions induced by drugs include extremely diverse clinical, biological and histological expressions that can take the aspect of any form of acute or chronic hepatobiliary disease. Hepatic lesions induced by drugs (LHIM) represent a histological and/or biochemical alteration caused and attributed to the consumption of a drug. Hepatic elastography (Fibroscan) represents a noninvasive method of quantification of hepatic fibrosis.

Material and method: We carried out a retrospective study and longitudinally prospective study that included a set of patients under treatment with Methotrexate, amounting to 76, divided into 2 subsets: a subset consisting of patients with hepatitis to Methotrexate, subset 1, of 23 patients, a subset of patients under treatment with Methotrexate but with normal hepatic samples, subset b, of 53 patients.

Results: We carried out fibroscan at all the patients treated with Methotrexate, obtaining a medium score of fibrosis of 6.23 for the subset a with hepatitis at Methotrexate and of 5.33 for the subset b with normal hepatic samples. We made a correlation between the cumulated dose of Methotrexate and the change of hepatic samples.

Conclusions: There is a significant correlation between hepatic fibrosis induced by Methotrexate and the cumulated dose of Methotrexate. The possibility of utilization of fibroscan which is a completely painless method, reproducible, for the monitoring of the treatment with Methotrexate both at patients with changed values of the hepatic tests as weir as those with normal values must be considered.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Bohan A. & Boyer J.L. (2002). Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis 22(2) 123-136. doi:

    • Crossref
    • Export Citation
  • 2. Dumitrascu D. (1997). Hepatic lesions induced by drugs.. In M. Grigorescu & O. Pascu (Eds) Clinical gastroenterology treaty vol II (pp. 283-297). Bucharest : Technical Publishing House.

  • 3. Farrel G.C. (1995). Importance of drug-induced liver disease. In: G.C. Farrel (ed) Drug-Induced Liver Diseases (pp 29-41) Edinburgh: Churchill Livingstone.

  • 4. Hagenbuch B. & Meier P.J. (2004). Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily new nomenclature and molecular/functional properties. Pflugers Arch 447(5) 653-665. doi:

    • Crossref
    • Export Citation
  • 5. Keppler D. & Konig J. (1997). Hepatic canalicular membrane 5: Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 11(7) 509-516.

  • 6. Keppler D. & Konig J. (2000). Hepatic secretion of conjugated drugs and endogenous substances. Semin Liver Dis 20(3) 265-272. doi:

    • Crossref
    • Export Citation
  • 7. Lecureur V. Courtois A. Payen L. Verhnet L. Guillouzo A. & Fardel O. (2000). Expression and regulation of hepatic drug and bile acid transporters. Toxicology 153(1-3) 203-219.

  • 8. Lee J. & Boyer J.L. (2000). Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 20(3) 373-384. doi:

    • Crossref
    • Export Citation
Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 411 245 4
PDF Downloads 151 81 1